showed that sorafenib decreased the activation of the PI3K/AKT/mTOR signaling axis in a mouse model of PTEN-deficient and castration-resistant prostate cancer, but there was no statistically significant reduction in the tumor burden. This evidence concerns the gene PTEN and prostate carcinoma.